| Literature DB >> 24656093 |
Jordi Genovés1, Frances Alameda2, Gemma Mancebo3, Josep Maria Solé1, Beatriz Bellosillo4, Belen Lloveras4, Silvia Agramunt1, Maria Teresa Baró4, Mercè Muset4, Beatriz Casado1, Laia Serrano5, Esther Miralpeix1, Ramon Carreras3.
Abstract
p16(INK4a) expression in dysplastic cervical lesions is related to high-risk human papillomavirus (HR-HPV) infection. The immunohistochemical expression of this protein in these lesions allows an increase in diagnostic reproducibility in biopsies and the introduction of prognostic factors in low-grade lesions. Here, we studied the immunohistochemical expression of p16 in 86 dysplastic cervical lesions, 54 cervical intraepithelial neoplasms-grade 1 (CIN-I), 23 CIN-II, and 9 CIN-III. In addition, we performed HPV detection and genotyping. We detected HR-HPV in 19/54 CIN-I, 21/23 CIN-II and 9/9 CIN-III cases. p16(INK4a) immunoreactivity was observed in 7/19 CIN-I HR-HPV-positive, 17/21 CIN-II HR-HPV-positive and all CIN-III cases. Immunoreactivity for p16(INK4a) was found in 7/54 CIN-I and in 17/23 CIN-II cases. In the follow-up, we detected 3 p16-positive high-grade squamous epithelial lesions (CIN-II and CIN-III) in the CIN-I/p16-negative group and 5 p16-positive high-grade squamous epithelial lesions cases in the CIN-II/p16-negative group. We conclude that p16 negativity in CIN-I and CIN-II biopsies does not always imply regression of the lesion and that the diagnosis of CIN-II should not be based solely on p16 results.Entities:
Keywords: Dysplasia; HPV; Uterine cervix; p16(INK4a)
Mesh:
Substances:
Year: 2013 PMID: 24656093 DOI: 10.1016/j.humpath.2013.10.035
Source DB: PubMed Journal: Hum Pathol ISSN: 0046-8177 Impact factor: 3.466